Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) EBT Margin (2021 - 2025)

Historic EBT Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 27873.57%.

  • SAB Biotherapeutics' EBT Margin changed N/A to 27873.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 68111.45%, marking a year-over-year increase of 711237300.0%. This contributed to the annual value of 3171.7% for FY2024, which is 12872000.0% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported EBT Margin of 27873.57% as of Q3 2025.
  • SAB Biotherapeutics' EBT Margin's 5-year high stood at 27873.57% during Q3 2025, with a 5-year trough of 8669.15% in Q4 2024.
  • For the 5-year period, SAB Biotherapeutics' EBT Margin averaged around 1589.32%, with its median value being 150.79% (2021).
  • In the last 5 years, SAB Biotherapeutics' EBT Margin tumbled by -79694700bps in 2023 and then surged by 179914300bps in 2025.
  • SAB Biotherapeutics' EBT Margin (Quarter) stood at 104.46% in 2021, then crashed by -248bps to 363.23% in 2022, then crashed by -1963bps to 7493.75% in 2023, then dropped by -16bps to 8669.15% in 2024, then soared by 422bps to 27873.57% in 2025.
  • Its EBT Margin was 27873.57% in Q3 2025, compared to 15203.74% in Q2 2025 and 15495.1% in Q1 2025.